Glucotrack, Inc. · NASDAQ:GCTK
Glucotrack — Investor Presentation (August 2024)
28 slides from Glucotrack's investor presentation, Aug 26, 2024
Slide 1: Advancing Diabetes Management
Advancing Diabetes Management Next Generation Continuous Blood Glucose Monitoring July 2024 © Copyright 2024. All rights reserved. Glucotrack.
Slide 2: Important Disclaimers
Important Disclaimers This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Without limitin
Slide 3: A Mission That Is Driven By People-Centric Values
A Mission That Is Driven By People-Centric Values Our mission is to push the boundaries of glucose sensor technology. Driven by people-centric design principles, our implantable Continuous Blood Glucose Monitoring (CBGM) technology establishes unmatched standards in accuracy, convenience, and indep
Slide 4: Investment Highlights
Investment Highlights Significant Unmet Differentiated, Strong Major Near-Term Need & Best-in-Class Management Expected Commercial Technology Team Milestones Opportunity • $9.8B global revenue in CGM • Revolutionary CBGM • Leadership with successful • First-In-Human clinical in 2023, with strong gro
Slide 5: Escalating Prevalence & Cost of Diabetes
Escalating Prevalence & Cost of Diabetes People Living with Diabetes (20-79 yrs.) Globally1 US Mortality & Morbidity3 Geography 2021 2045 Increase US 32 M 36 M 13 % Europe 61 M 69 M 13 % ROW 444 M 679 M 53 % LEADING CAUSES OF DEATH, 2022 800,000 700,000 600,000 500,000 400,000 300,000 Global Health
Slide 6: CGM Market – Global 2023 revenue of $9.8 Billion
CGM Market – Global 2023 revenue of $9.8 Billion1 Global Quarterly Revenue (millions) Key Launches & Milestones Driving Growth 1999 In clinic CGMS (MARD 20’s%) 2006 1st Home Use CGM launched 2012 iPhone connectivity 2014 Caregiver app functionality 2015 CGM MARDs of 9% 2017 1st Factory calibration;
Slide 7: Unaddressed Patient Needs Are A Catalyst for Future Growth
Unaddressed Patient Needs Are A Catalyst for Future Growth 44% Longer sensor wear 64% What Patients Still Want 1. Long-term use 39% 2. Minimal warm up time Shorter sensor warmup time 60% 3. Greater accuracy (perceived, no lag) 4. Minimize on-body device issues 27% Smaller or thinner CGM sensor 5. Be
Slide 8: Introducing A Novel Approach to Managing Glucose with Best-in-Class Potential
Introducing A Novel Approach to Managing Glucose with Best-in-Class Potential • Developed using best-in-class glucose monitoring and cardiac monitoring technology • Differentiated glucose monitoring technology which aims to combine the best of BGM & CGM – Measures blood glucose vs interstitial fluid
Slide 9: Preclinical Data Shows Highly Accurate CBGM
Preclinical Data Shows Highly Accurate CBGM 9 © Copyright 2024. All rights reserved. Glucotrack.
Slide 10: Appealing Product Concept for Patients
Appealing Product Concept for Patients • Over 50% of respondents (N=757) are interested in the implantable CBGM concept. Current CGM users had the highest interest and likelihood to acquire, followed by CGM ex-users. Most Appealing Aspects Sounds like the best way to get BG readings. What Patients W
Slide 11: Attractive Procedure Opportunity for Interventionalists
Attractive Procedure Opportunity for Interventionalists • N=25 Interventional Cardiologists & N=25 Interventional Radiologists from 25 states; 40% of patients with diabetes (on average) • 49 of 50 respondents would likely accept patient referrals from Endocrinologists to perform this procedure. 49 o
Slide 12: CBGM: Next Generation Innovation in Glucose Monitoring
CBGM: Next Generation Innovation in Glucose Monitoring More Accurate Glucose Measurement • Measures blood, the gold standard for accuracy, with minimal lag time • Potential to advance standard of care for diabetes management (ability to automatically bolus with meal, not after, when incorporated in
Slide 13: Estimated US CBGM Opportunity
Estimated US CBGM Opportunity • Pre-2023, CGM market defined as: Market Opportunity – T1D Total US Diabetes Market (T1D & T2D) 38M – T2D on intensive insulin therapy # T1D 1.8M1 • Post-2023 CMS expansion, CGM market # T2D Insulin Intensive Therapy (4+ injections/day) 2.4M1 now includes: # T2D Basal
Slide 14: Key Catalysts For Growth
Key Catalysts For Growth • Successful completion of first preclinical study – Assessed implant technique and confirmed device safety – Confirmed high level of accuracy – MARD of 8.1% at Day 30 and 4.5% at Day 60 • Initiation of long-term preclinical studies – Assessing sensor accuracy and longevity
Slide 15: Development and Regulatory Timeline
Development and Regulatory Timeline 2024 2025 2026 2027 2028 Sheep Preclinical Study 1 Animal Sheep Studies Study 2 FIH Acute (N=10) FIH Chronic (N=20) Human Clinical Studies US Pilot (N=40) US Pivotal Study (N=100-200) Product Product Development & Validation Development FDA Pre-submission Launch R
Slide 16: Future Expansion Opportunity: Painful Diabetic Neuropathy
Future Expansion Opportunity: Painful Diabetic Neuropathy • Painful Diabetic Neuropathy (PDN) is a progressive neurological disorder that affects approx 1/5 of people with diabetes (> 7M individuals in the US)1 – Symptoms include paresthesia, burning, and shooting pain Type of pain experienced by re
Slide 17: Epidural Glucose Monitoring for PDN Patients
Epidural Glucose Monitoring for PDN Patients • Spinal Cord Stimulation (SCS) technology recently FDA-approved as treatment option which provides significant long-term pain relief to PDN patients – SCS is the 2nd most implanted technology in the US – Utilizes similar lead technology as cardiac pacema
Slide 18: Preclinical Epidural Chronic Study – Day 1 Accuracy Confirmed
Preclinical Epidural Chronic Study – Day 1 Accuracy Confirmed Glucotrack Commercial CGM 18 © Copyright 2024. All rights reserved. Glucotrack.
Slide 19: Preclinical Epidural Chronic Study – Week 6 Accuracy Confirmed
Preclinical Epidural Chronic Study – Week 6 Accuracy Confirmed Glucotrack Commercial CGM 19 © Copyright 2024. All rights reserved. Glucotrack.
Slide 20: Our Advanced Glucose Sensor Technology Offers Multiple Opportunities for Success
Our Advanced Glucose Sensor Technology Offers Multiple Opportunities for Success CBGM Epidural Glucose Monitoring via • Interventional Cardiologist / SCS integration Radiologist Call Point & • Neurosurgeon Call Point & Reimbursement Pathway Reimbursement Pathway • Target: Diabetes population • Targe
Slide 21: Proven Execution with Seasoned Leadership Team
Proven Execution with Seasoned Leadership Team Paul has many years developing innovative diabetes management technologies, including as VP of R&D at MetaCure, a neurostimulator Paul V. Goode, PhD device for Type 2 diabetes; Director of Engineering and Algorithm Development at Dexcom, a global contin
Slide 22: CBGM & Beyond: A Compelling Investment Opportunity
CBGM & Beyond: A Compelling Investment Opportunity Large Addressable Market & Favorable Macro Trends Differentiated Product And Commercial Opportunity Accelerating Adoption Innovative Pipeline • $9.8B global market for CGM in 2023, • Diabetes is a significant global health • Leveraging established w
Slide 23: Facts and Cap Table (as of July 5, 2024)
Facts and Cap Table (as of July 5, 2024) Exchange: Ticker NASDAQ: GCTK Headquarters Total Shares Issued & Outstanding 5,478,436 Rutherford, NJ Invested to date Options and Warrants 477,881 (Exercise price $2.45-$4.95) ~ $75,000,000 Stock Price Fully Diluted 5,956,317 $1.74 52 Week Range Market Cap $
Slide 24: APPENDIX
APPENDIX © Copyright 2024. All rights reserved. Glucotrack.
Slide 25: Company History Shows Willingness To Adapt to Market
Company History Shows Willingness To Adapt to Market 2001 Company founded as Integrity Applications, Inc. 2010 Company goes public on the OTC Markets under symbol IGAP 2013 Obtained CE Mark for non-invasive glucose monitoring technology 2018 Limited commercial release of non-invasive glucose monitor
Slide 26: Experienced, Dedicated Board of Directors
Experienced, Dedicated Board of Directors Mr. Malavé brings more than 30 years of leadership in the MedTech industry, primarily in diabetes management. He has extensive expertise in product development, operations, marketing, Luis J. Malave, Chair strategic partnerships, and FDA regulatory strategy.
Slide 27: Glucose Monitoring Options Available Today
Glucose Monitoring Options Available Today Blood Glucose Monitors Continuous Glucose Monitors (CGM’s) (BGM’s) Spot/Point-in-Time – measures Continuous – measures glucose in interstitial fluid every few Method glucose level in blood at a minutes for duration of sensor life single point in time Compan
Slide 28: Thank You
Thank You 28 © Copyright 2024. All rights reserved. Glucotrack.